COPD (Chronic Obstructive Pulmonary Disease)SCOOPNCT07923656
The Aim of the Study is to Decipher the Alterations in Signalling Pathways of Skeletal Muscle Stem Cells (Satellite Cells (SCs)) in Individuals With COPD, as Well as to Examine the Effect of Exercise Training on SCs.
A study testing Exercise training in people with COPD (Chronic Obstructive Pulmonary Disease) and Sarcopenia in Elderly, run by University Hospital, Bordeaux at 3 sites in France.
Trial summary
The aim of the study is to decipher the alterations in signalling pathways of skeletal muscle stem cells (satellite cells (SCs)) in individuals with COPD, as well as to examine the effect of exercise training on SCs. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- COPD (Chronic Obstructive Pulmonary Disease), Sarcopenia in Elderly, Skeletal Muscle Atrophy
- What is being tested?
- Exercise training
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 26 participants
- Where
- 3 sitesFrance
- Study dates
- 15 Nov 2026to 15 Mar 2030
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adult male or female (age 18 years or older);
- Having a diagnosis of COPD according to the GOLD (Global Initiative for Lung Disease) 2024 criteria, i.e. a non-reversible bronchial obstruction in spirometry with a post-bronchodilator Tiffeneau coefficient < 70%;
- Less than or equal to 75 years of age;
- Must benefit from exercise retraining sessions or respiratory rehabilitation as part of the management of COPD;
- Person affiliated to or beneficiary of a social security scheme (excluding State Medical Aid (AME));
- Free, informed and written consent signed by the participant or by a third party (in the event of the participant's physical disability) and the investigator (no later than the day of inclusion and before any review required by the research).
Who cannot join
- Moderate or severe acute exacerbation of COPD, or acute intercurrent condition (e.g., infection) that has been ongoing or resolved for less than 4 weeks;
- Systemic corticosteroid therapy in progress or stopped for less than 4 weeks;
- Contraindication to respiratory rehabilitation: tight aortic stenosis, unstable heart failure, active thromboembolic disease, ventricular aneurysm, uncontrolled arrhythmias;
- Contraindication to muscle biopsy: acquired or innate haemostasis disorders, anticoagulant treatment or double anti-platelet aggregation; contraindication to lidocaine: known hypersensitivity, patients with recurrent porphyrias;
- Presence of a concomitant muscle pathology, innate (e.g., genetic myopathy) or acquired (e.g., myositis, progressive cancer);
- Pregnant or breastfeeding woman;
Show all 9Show fewer
- Patient under guardianship or curatorship;
- Refusal to participate in the study.
- Hemostasis disorders.
Trial locations and contacts
3 sites in 1 country. Contact the study team or a site near you to ask about taking part.
France3 sites
Hôpital Henri-Mondor
Créteil, 94000
Laurent BOYER, MD, PhD, +33(0)1 49 81 26 81, laurent.boyer@aphp.fr
Hôpital Pitié-Salpêtrière
Paris, 75013
Romy RATSIHORIMANANA, MD, +33(0)1 42 16 77 99, romy.ratsihorimanana@aphp.fr
CHU de Bordeaux
Pessac, 33400
Pauline HENROT, MD, +33(0)5 57 65 65 13, pauline.henrot@chu-bordeaux.fr
Pauline HENROT, MD
About this study
Official title: Study of Satellite Cells in COPD-associated sarcOPenia (Satellite Cells in COPD Sarcopenia) : Exploratory Cohort Study for Translational Research
The aim of the study is to decipher the alterations in signalling pathways of skeletal muscle stem cells (satellite cells (SCs)) in individuals with COPD, as well as to examine the effect of exercise training on SCs. To this end, the team will perform an exhaustive evaluation of lung and muscle function, including exercise capacity, as well as muscle biopsies, before and after a 2-months rehabilitation program. This study should provide new therapeutic avenues for COPD-associated sarcopenia.
Read the detailed description
Chronic obstructive pulmonary disease (COPD) is now to be considered as a multimorbid disease, originating from a combination of several risk factors (respiratory events in childhood, exposure to inhaled particles, physical inactivity, etc.), and simultaneously affecting several organs. This multi-organ impairment is likely to arise from common biological processes such as systemic inflammation or repair failure. Studying these processes in an organ that is easily accessible to biopsy, such as skeletal muscle, can help in the overall management of COPD. Skeletal muscle wasting (or sarcopenia: loss of muscle mass and force) is also a major comorbidity in COPD, both frequent and associated to increased mortality. Muscle stem cells (satellite cells) are responsible for repairing skeletal muscle tissue after injury, notably after micro-lesions induced by exercise. However, they have been scarcely studied in COPD. In the present project, the team proposes to study repair abnormalities in skeletal muscle tissue by comparing the signalling pathways activated in satellite cells of patients with COPD, before and after a respiratory rehabilitation programme (20 sessions over 8 to 12 weeks). The team will carry out an exhaustive respiratory and muscular assessment at inclusion and at the end of the 20 sessions, evaluating in particular respiratory function and exercise capacity (Pulmonary Function Tests, cardio-pulmonary exercise testing with VO2max measurement, 6-minute walking test, handgrip test) as well as a quadricipital muscle biopsy with the modified Bergström's technique. Muscle biopsies will be used to culture satellite cells and assess their regenerative capacity in vitro, as well as to analyse dysregulated signalling pathways at the transcriptomic level with single-cell RNAsequencing. The results should help to identify new therapeutic avenues for the comprehensive management of multimorbid COPD.
- Conditions
- COPD (Chronic Obstructive Pulmonary Disease), Sarcopenia in Elderly, Skeletal Muscle Atrophy, Cachexia-Anorexia Syndrome
- Being tested
- Exercise training
- Keywords
- COPD, pulmonary rehabilitation, sarcopenia, skeletal muscle wasting;, satellite cells, single-nuclei RNAsequencing, single-cell RNAsequencing
- Medical subject headings
- Pulmonary Disease, Chronic Obstructive, Muscular Atrophy, Sarcopenia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Exercise trainingProcedure or surgery
Patients will undergo an exhaustive respiratory and muscular check-up (including quadridipital muscle biopsies) at inclusion and at the end of the respiratory rehabilitation program (a minimum of 20 sessions at a rate of 2 to 3 sessions per week for 8 to 12 weeks).
| Study group | Role | What they receive |
|---|---|---|
| Men or women (adults) with a diagnosis of COPD according to GOLD criteria | Experimental | Not described Receives: Procedure: Exercise training |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in single-cell gene expression profile of muscle satellite cells after pulmonary rehabilitation
Intra-individual comparison of messenger RNA (mRNA) expression in muscle satellite cells isolated from quadriceps muscle biopsies collected before and after the pulmonary rehabilitation programme. Satellite cells will be isolated and analysed using single-cell and single-nucleus RNA sequencing. The outcome is the change in the gene-expression profile, including differentially expressed genes and associated molecular signalling pathways, between baseline and the end of rehabilitation.
Measured: Day 1 (baseline, Visit 1) and Week 10 (± 2 weeks; Visit 2)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Nov 2026
- Study start15 Nov 2026 (estimated)
- Primary completion15 Mar 2030 (estimated)
- Study completion15 Mar 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for COPD (Chronic Obstructive Pulmonary Disease)Studies of the same condition, open and under way.
- More trials run by University Hospital, BordeauxThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 26 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Bordeaux
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Pauline HENROT, Principal investigator, University Hospital, Bordeaux
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07923656
- Sponsor's protocol ID
- CHUBX 2026/005
- Other IDs
- 2026-A00609-42
- Acronym
- SCOOP
- Status last verified
- Oct 2026
- First submitted
- 16 Oct 2026
- Last updated
- 6 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The data is available from Dr HENROT . An email can be sent to her so that she can contact the data manager and owner, the Bordeaux University Hospital. The data can be made available after contractual agreement.
Study at a glance
From the registry record, last updated by the sponsor on 6 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study of Satellite Cells in COPD-associated sarcOPenia (Satellite Cells in COPD Sarcopenia) : Exploratory Cohort Study for Translational Research
- ClinicalTrials.gov ID
- NCT07923656
- Acronym / sponsor ID
- SCOOP / CHUBX 2026/005
- Conditions
- COPD (Chronic Obstructive Pulmonary Disease), Sarcopenia in Elderly, Skeletal Muscle Atrophy, Cachexia-Anorexia Syndrome
- Keywords
- COPD, pulmonary rehabilitation, sarcopenia, skeletal muscle wasting;, satellite cells, single-nuclei RNAsequencing, single-cell RNAsequencing
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 26 participants (estimated)
- Lead sponsor
- University Hospital, BordeauxUniversity, hospital or other
- Study start
- 15 Nov 2026 (estimated)
- Primary completion
- 15 Mar 2030 (estimated)
- Study completion
- 15 Mar 2030 (estimated)
- First posted
- 6 Nov 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the study is to decipher the alterations in signalling pathways of skeletal muscle stem cells (satellite cells (SCs)) in individuals with COPD, as well as to examine the effect of exercise training on SCs. To this end, the team will perform an exhaustive evaluation of lung and muscle function, including exercise capacity, as well as muscle biopsies, before and after a 2-months rehabilitation program. This study should provide new therapeutic avenues for COPD-associated sarcopenia.
Detailed description
Chronic obstructive pulmonary disease (COPD) is now to be considered as a multimorbid disease, originating from a combination of several risk factors (respiratory events in childhood, exposure to inhaled particles, physical inactivity, etc.), and simultaneously affecting several organs. This multi-organ impairment is likely to arise from common biological processes such as systemic inflammation or repair failure. Studying these processes in an organ that is easily accessible to biopsy, such as skeletal muscle, can help in the overall management of COPD. Skeletal muscle wasting (or sarcopenia: loss of muscle mass and force) is also a major comorbidity in COPD, both frequent and associated to increased mortality. Muscle stem cells (satellite cells) are responsible for repairing skeletal muscle tissue after injury, notably after micro-lesions induced by exercise. However, they have been scarcely studied in COPD. In the present project, the team proposes to study repair abnormalities in skeletal muscle tissue by comparing the signalling pathways activated in satellite cells of patients with COPD, before and after a respiratory rehabilitation programme (20 sessions over 8 to 12 weeks). The team will carry out an exhaustive respiratory and muscular assessment at inclusion and at the end of the 20 sessions, evaluating in particular respiratory function and exercise capacity (Pulmonary Function Tests, cardio-pulmonary exercise testing with VO2max measurement, 6-minute walking test, handgrip test) as well as a quadricipital muscle biopsy with the modified Bergström's technique. Muscle biopsies will be used to culture satellite cells and assess their regenerative capacity in vitro, as well as to analyse dysregulated signalling pathways at the transcriptomic level with single-cell RNAsequencing. The results should help to identify new therapeutic avenues for the comprehensive management of multimorbid COPD.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Men or women (adults) with a diagnosis of COPD according to GOLD criteria | Experimental | Procedure: Exercise training |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Adult male or female (age 18 years or older);
- Having a diagnosis of COPD according to the GOLD (Global Initiative for Lung Disease) 2024 criteria, i.e. a non-reversible bronchial obstruction in spirometry with a post-bronchodilator Tiffeneau coefficient < 70%;
- Less than or equal to 75 years of age;
- Must benefit from exercise retraining sessions or respiratory rehabilitation as part of the management of COPD;
- Person affiliated to or beneficiary of a social security scheme (excluding State Medical Aid (AME));
Key exclusion criteria (9 listed)
- Moderate or severe acute exacerbation of COPD, or acute intercurrent condition (e.g., infection) that has been ongoing or resolved for less than 4 weeks;
- Systemic corticosteroid therapy in progress or stopped for less than 4 weeks;
- Contraindication to respiratory rehabilitation: tight aortic stenosis, unstable heart failure, active thromboembolic disease, ventricular aneurysm, uncontrolled arrhythmias;
- Contraindication to muscle biopsy: acquired or innate haemostasis disorders, anticoagulant treatment or double anti-platelet aggregation; contraindication to lidocaine: known hypersensitivity, patients with recurrent porphyrias;
- Presence of a concomitant muscle pathology, innate (e.g., genetic myopathy) or acquired (e.g., myositis, progressive cancer);
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Exercise trainingPatients will undergo an exhaustive respiratory and muscular check-up (including quadridipital muscle biopsies) at inclusion and at the end of the respiratory rehabilitation program (a minimum of 20 sessions at a rate of 2 to 3 sessions per week for 8 to 12 weeks). | Procedure or surgery | Men or women (adults) with a diagnosis of COPD according to GOLD criteria |
Primary outcome
Change in single-cell gene expression profile of muscle satellite cells after pulmonary rehabilitation
Time frame: Day 1 (baseline, Visit 1) and Week 10 (± 2 weeks; Visit 2)
Intra-individual comparison of messenger RNA (mRNA) expression in muscle satellite cells isolated from quadriceps muscle biopsies collected before and after the pulmonary rehabilitation programme. Satellite cells will be isolated and analysed using single-cell and single-nucleus RNA sequencing. The outcome is the change in the gene-expression profile, including differentially expressed genes and associated molecular signalling pathways, between baseline and the end of rehabilitation.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Nov 2026.
- Individual participant dataSharing planned: Yes. The data is available from Dr HENROT . An email can be sent to her so that she can contact the data manager and owner, the Bordeaux University Hospital. The data can be made available after contractual agreement.
Related trials for COPD (Chronic Obstructive Pulmonary Disease)
Active, not recruiting
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
COPD, Smoking
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Not yet recruitingPhase 2
Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Active, not recruitingPhase 1
A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
Pulmonary Disease, Chronic Obstructive
RecruitingPhase 2
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis
Chronic Obstructive Pulmonary Disease With Chronic Bronchitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Pauline HENROT principal investigator
University Hospital, Bordeaux
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Exercise training in people with COPD (Chronic Obstructive Pulmonary Disease) and Sarcopenia in Elderly, run by University Hospital, Bordeaux at 3 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 6 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Pauline HENROT, MD (+33(0)5 57 65 65 13, pauline.henrot@chu-bordeaux.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in single-cell gene expression profile of muscle satellite cells after pulmonary rehabilitation (time frame: Day 1 (baseline, Visit 1) and Week 10 (± 2 weeks; Visit 2)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2026.